What You Should Know:– Nebraska-based Bluestem Health today announced it has launched an AI-based virtual medical assistant powered by Mediktor. This is available for both established and non-established patients to efficiently assess their symptoms…
Continue Reading![Understanding the Healthcare Cybersecurity War and How to Defend Against It [Sponsored]](https://www.mediformatica.com/wp-content/uploads/2023/02/understanding-the-healthcare-cybersecurity-war-and-how-to-defend-against-it-sponsored.jpg)
The series of attacks on our healthcare infrastructure, particularly hospitals where ransomware attacks are on the rise, is a worrying trend that puts lives in jeopardy. A ransomware attack could mean the difference between…
Continue Reading
Due to Covid-19, many companies moved to a hybrid work model, leading to their buildings being largely underutilized. Blue Cross and Blue Shield of North Carolina (Blue Cross NC), is taking advantage of its quieter workspace to fight food insecurity in its local communities.
Due to fewer employees working onsite, Blue Cross…
Although 2022 has brought on a greater sense of normalcy, the past few years have distracted us from one of the most overlooked epidemics plaguing healthcare: prescription drug abuse.
Before Covid-19 diverted attention away from this problem, President Trump signed on to the SUPPORT for Patients and Communities Act of 2018, instating sweeping legislation for initiatives to address the opioid epidemic. The bill, among other initiatives, requires electronic prescriptions for controlled substances (EPCS) for any covered part D drug. Although the official start of the mandate was delayed two years to January 1, 2023, the importance of this federal intervention cannot be…
Geographic atrophy, an eye disorder that starts as a loss of central vision and progressively worsens to total blindness, now has its first treatment. The FDA on Friday approved an Apellis Pharmaceuticals drug that slows the progression of this disease, which affects more than 1 million people in the U.S.
Approval of the Apellis drug, pegcetacoplan, covers all patients with geographic atrophy, a broad label that reflects the representative patient population tested in pivotal studies, Chief Medical Officer Caroline Baumal said during a Friday evening conference call. The Waltham, Massachusetts-based company plans to launch the drug in March, marketing the product under…
Pharmacy Benefit Managers (PBMs) took a hit from lawmakers during a Thursday hearing held by the Senate Commerce Committee, with some questioning why the drug middlemen are even necessary.
“The way I see the situation on PBMs, I don’t know why the hell they even exist,” said Sen. Jon Tester, D-Montana. “They were set up with all the right reasons … But what I see them doing in my state, I don’t think the consumer gets much benefit and they’re shutting down small businesses on main street right and left and those are called our local neighborhood pharmacies.” The hearing discussed how…
The pandemic has forced healthcare organizations to rely heavily on telehealth services. In 2020, virtual visits accounted for more than a quarter of all outpatient visits in the U.S., and they’ve been steadily increasing since then. But there is a flip side to this trend. Recent data shows that telehealth is declining in healthcare, which could create a burden for both healthcare systems and patients. Let’s take a look at why this is happening and what can be done about it.
Reasons behind the decline There are several factors driving the decline in telehealth utilization in healthcare settings. One reason is cost…
A Chiesi Farmaceutici drug for a rare enzyme deficiency is now approved by the FDA, making it the first U.S. treatment for a disorder that leads to a range of cognitive and muscle problems.
The regulatory decision announced late Thursday covers the treatment of children and adults who have alpha-mannosidosis (AM), a disease caused by a genetic mutation that leads to defective or inactive forms of an enzyme called alpha-D-mannosidase. Chiesi’s drug, velmanase alfa, is an engineered version of that enzyme. The privately held Italian company will market its new FDA-approved drug as Lamzede, the same name for the product in Europe,…
The current Adderall shortage is of serious concern to both patients who have attention deficit hyperactivity disorder (ADHD) and clinicians. This shortage cannot be quickly alleviated by a simple increase in the amount of medication manufactured, unless the upper limit to the amount of Adderall’s active ingredient that can be manufactured in a given year is raised by the Drug Enforcement Agency (DEA). The limit has been imposed because the active ingredient can be abused as a recreational drug. It is necessary to control the supply of any medication with abuse liability, but this must be achieved without compromising the legitimate…
Continue Reading
‘Tripledemic’ concerns have been on the rise with the collision of flu, Covid-19, and respiratory syncytial virus (RSV) wreaking havoc in clinics and hospitals. Yet staff are expected to provide smooth, fast, and effective care journeys for all, no matter the volume of patients. We know, however, that everything doesn’t always go as planned when patient traffic explodes. Bottlenecks like long wait times and limited appointment options inevitably skyrocket, and staff bear the brunt of patients who (understandably) want to be seen immediately, in conjunction with staff members intermittently being out sick themselves.
Living in an environment of extreme health unpredictability affects…
